Randomized assessment of rapid endovascular treatment of ischemic stroke

Mayank Goyal, Andrew M. Demchuk, Bijoy K. Menon, Muneer Eesa, Jeremy L. Rempel, John Thornton, Daniel Roy, Tudor G. Jovin, Robert A. Willinsky, Biggya L. Sapkota, Dar Dowlatshahi, Donald F. Frei, Noreen R. Kamal, Walter J. Montanera, Alexandre Y. Poppe, Karla J. Ryckborst, Frank L. Silver, Ashfaq Shuaib, Donatella Tampieri, David WilliamsOh Young Bang, Blaise W. Baxter, Paul A. Burns, Hana Choe, Ji Hoe Heo, Christine A. Holmstedt, Brian Jankowitz, Michael Kelly, Guillermo Linares, Jennifer L. Mandzia, Jai Shankar, Sung Il Sohn, Richard H. Swartz, Philip A. Barber, Shelagh B. Coutts, Eric E. Smith, William F. Morrish, Alain Weill, Suresh Subramaniam, Alim P. Mitha, John H. Wong, Mark W. Lowerison, Tolulope T. Sajobi, M. D. Hill

Research output: Contribution to journalArticlepeer-review

4169 Citations (Scopus)


Background: Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence despite alteplase treatment. We evaluated rapid endovascular treatment in addition to standard care in patients with acute ischemic stroke with a small infarct core, a proximal intracranial arterial occlusion, and moderate-to-good collateral circulation. Methods: We randomly assigned participants to receive standard care (control group) or standard care plus endovascular treatment with the use of available thrombectomy devices (intervention group). Patients with a proximal intracranial occlusion in the anterior circulation were included up to 12 hours after symptom onset. Patients with a large infarct core or poor collateral circulation on computed tomography (CT) and CT angiography were excluded. Workflow times were measured against predetermined targets. The primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. A proportional odds model was used to calculate the common odds ratio as a measure of the likelihood that the intervention would lead to lower scores on the modified Rankin scale than would control care (shift analysis). Results: The trial was stopped early because of efficacy. At 22 centers worldwide, 316 participants were enrolled, of whom 238 received intravenous alteplase (120 in the intervention group and 118 in the control group). In the intervention group, the median time from study CT of the head to first reperfusion was 84 minutes. The rate of functional independence (90-day modified Rankin score of 0 to 2) was increased with the intervention (53.0%, vs. 29.3% in the control group; P<0.001). The primary outcome favored the intervention (common odds ratio, 2.6; 95% confidence interval, 1.7 to 3.8; P<0.001), and the intervention was associated with reduced mortality (10.4%, vs. 19.0% in the control group; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 3.6% of participants in intervention group and 2.7% of participants in control group (P = 0.75). Conclusions: Among patients with acute ischemic stroke with a proximal vessel occlusion, a small infarct core, and moderate-to-good collateral circulation, rapid endovascular treatment improved functional outcomes and reduced mortality. (Funded by Covidien and others; ESCAPE ClinicalTrials.gov number, NCT01778335.)

Original languageEnglish
Pages (from-to)1019-1030
Number of pages12
JournalNew England Journal of Medicine
Issue number11
Publication statusPublished - 2015 Mar 12

Bibliographical note

Publisher Copyright:
Copyright © 2015 Massachusetts Medical Society.

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Randomized assessment of rapid endovascular treatment of ischemic stroke'. Together they form a unique fingerprint.

Cite this